January 4, 2017: Orexigen Therapeutics, Inc. unveiled “Brains Behind Weight Loss,” a new, national direct-to-consumer advertising campaign demonstrating to patients how the brain plays an important role in weight loss. The campaign will underscore how CONTRAVE (naltrexone HCl/bupropion HCl), an FDA-approved prescription weight-loss medicine, is believed to work on two important areas of the brain the hypothalamus (hunger center) to reduce hunger and the mesolimbic reward system to help control cravings. (The exact neurochemical effects of CONTRAVE leading to weight loss are not fully understood). CONTRAVE is the number one prescribed weight loss brand in the United States.
The CONTRAVE campaign is Orexigen’s first collaboration with Young & Rubicam New York since being tapped as agency of record. Kicking off at the start of the season amidst New Year’s resolutions, the campaign emphasizes the strong connection between the brain and weight loss. The visually intriguing images feature real women who arrange themselves to simulate depictions of the human brain.
December 26, 2016: Orexigen Therapeutics recently announced that its wholly owned subsidiary Orexigen Therapeutics Ireland Ltd. and Biologix FZCO, have executed a commercialization and distributorship agreement in the Middle East for Contrave (naltrexone HCl / bupropion HCl prolonged release) monotherapy for weight management in overweight or obese adult patients.
This agreement covers ten countries in the Middle East: Saudi Arabia, the United Arab Emirates, Kuwait, Oman, Qatar, Bahrain, Lebanon, Jordan, Iraq, and Iran. Under the terms of the agreement, Biologix will be responsible for obtaining regulatory approvals and local product registrations in each of the ten countries and for all commercialization activities. Orexigen will supply Contrave to Biologix at an agreed transfer price. Biologix expects Contrave to be available for patients in some countries starting in the third quarter of 2017.
December 8, 2016: Orexigen Therapeutics announced that its wholly owned subsidiary Orexigen Therapeutics Ireland Ltd. and Consilient Health Ltd. had executed a commercialization and distributorship agreement for Mysimba (naltrexone HCl / bupropion HCl prolonged release) in the UK and Ireland. Mysimba is approved by the European Medicines Agency, as an adjunct to a reduced-calorie diet and increased physical activity, for the management of weight in adult patients (=18 years) with an initial Body Mass Index (BMI) of = 30 kg/m2 (obese), or = 27 kg/m2 to November 16, 2016: Orexigen Therapeutics announces the presentation of data for OREX-1019, a preclinical candidate for treatment and management of drug addiction Announced the presentation of preclinical data for OREX-1019 (BU10119) at Neuroscience 2016, the 46th annual meeting of the Society of Neuroscience, being held this week in San Diego. OREX-1019 is being evaluated by Orexigen as a treatment for opioid and cocaine addiction and was exclusively licensed by the company in 2015. OREX-1019 is a member of an orvinol compound series developed by Dr. Stephen Husbands, Ph.D. at the University of Bath in the United Kingdom.The data presented this week, “A buprenorphine analog attenuates drug-primed and stress-induced cocaine reinstatement,” was assembled by a team of researchers led by Dr. John Traynor, Ph.D. of the University of Michigan. The biochemical profile of several members of the licensed orvinol compound series, including OREX-1019, demonstrates reduced Mu opioid receptor activity compared to buprenorphine. The presented data provide in vivo evidence for the compound’s therapeutic potential in drug addiction management and suggest a wider use in cocaine addiction.
November 8, 2016: Orexigen Therapeutics announces commercialization and distributorship agreement with Valeant for Contrave (naltrexone HCl / bupropion HCl extended release) in Australia and New Zealand Announced that Valeant Pharmaceuticals International, Inc. (Valeant), through a wholly-owned subsidiary, will commercialize Contrave (naltrexone HCl / bupropion HCl extended release) in Australia and New Zealand. Under the terms of the agreement between Valeant and Orexigen’s wholly owned subsidiary, Orexigen Therapeutics Ireland Ltd., Valeant will be responsible for obtaining regulatory approvals and for all commercialization activities. Orexigen will supply Contrave tablets to Valeant for an agreed transfer price and certain potential sales milestone payments. Orexigen expects Valeant to file for regulatory approvals in both countries in the first half of 2017.
Orexigen and Valeant Pharmaceuticals International, Inc. previously announced commercialization agreements for Mysimba (naltrexone HCl / bupropion HCl prolonged release) in 20 countries in Central and Eastern Europe and Contrave in Canada and South Africa.
Orexigen Therapeutics Stock Chart
Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. Orexigen developed Contrave (naltrexone HCl and bupropion HCl extended-release), which is approved in the United States. Orexigen’s strategy for Contrave is to pursue marketing authorizations worldwide and pharmaceutical partnerships for global commercialization.